JP2019535761A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535761A5 JP2019535761A5 JP2019527497A JP2019527497A JP2019535761A5 JP 2019535761 A5 JP2019535761 A5 JP 2019535761A5 JP 2019527497 A JP2019527497 A JP 2019527497A JP 2019527497 A JP2019527497 A JP 2019527497A JP 2019535761 A5 JP2019535761 A5 JP 2019535761A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- pharmaceutically acceptable
- acceptable salt
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 201000010099 disease Diseases 0.000 claims 9
- 208000024891 symptom Diseases 0.000 claims 9
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 101000764872 Homo sapiens Transient receptor potential cation channel subfamily A member 1 Proteins 0.000 claims 6
- 208000027601 Inner ear disease Diseases 0.000 claims 6
- 208000002193 Pain Diseases 0.000 claims 6
- 208000003251 Pruritus Diseases 0.000 claims 6
- 102100026186 Transient receptor potential cation channel subfamily A member 1 Human genes 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 5
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 229910052805 deuterium Inorganic materials 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 3
- 206010011224 Cough Diseases 0.000 claims 3
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 206010021143 Hypoxia Diseases 0.000 claims 3
- 206010021639 Incontinence Diseases 0.000 claims 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 3
- 206010037660 Pyrexia Diseases 0.000 claims 3
- 208000029061 Temperature regulation disease Diseases 0.000 claims 3
- 208000026723 Urinary tract disease Diseases 0.000 claims 3
- 125000004450 alkenylene group Chemical group 0.000 claims 3
- 125000002947 alkylene group Chemical group 0.000 claims 3
- 206010003246 arthritis Diseases 0.000 claims 3
- 208000006673 asthma Diseases 0.000 claims 3
- 230000017531 blood circulation Effects 0.000 claims 3
- 125000002993 cycloalkylene group Chemical group 0.000 claims 3
- 230000003247 decreasing effect Effects 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 230000004064 dysfunction Effects 0.000 claims 3
- 230000002496 gastric effect Effects 0.000 claims 3
- 230000007954 hypoxia Effects 0.000 claims 3
- 208000027866 inflammatory disease Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 208000023504 respiratory system disease Diseases 0.000 claims 3
- 208000014001 urinary system disease Diseases 0.000 claims 3
- 239000004480 active ingredient Substances 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- 230000001105 regulatory effect Effects 0.000 claims 2
- -1 -OCHF 2 Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016107423 | 2016-11-28 | ||
| CNPCT/CN2016/107423 | 2016-11-28 | ||
| CN201711122317.2 | 2017-11-14 | ||
| CN201711122317 | 2017-11-14 | ||
| PCT/EP2017/080571 WO2018096159A1 (en) | 2016-11-28 | 2017-11-27 | Oxadiazolones as transient receptor potential channel inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535761A JP2019535761A (ja) | 2019-12-12 |
| JP2019535761A5 true JP2019535761A5 (enExample) | 2021-01-07 |
| JP7171567B2 JP7171567B2 (ja) | 2022-11-15 |
Family
ID=60473538
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019527497A Active JP7171567B2 (ja) | 2016-11-28 | 2017-11-27 | 一過性受容体電位型チャネル阻害剤としてのオキサジアゾロン類 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US10913742B2 (enExample) |
| EP (1) | EP3544979B1 (enExample) |
| JP (1) | JP7171567B2 (enExample) |
| CN (1) | CN110225911B (enExample) |
| TW (1) | TW201831477A (enExample) |
| WO (1) | WO2018096159A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018162607A1 (en) | 2017-03-07 | 2018-09-13 | F. Hoffmann-La Roche Ag | Oxadiazole transient receptor potential channel inhibitors |
| US10710994B2 (en) | 2018-03-19 | 2020-07-14 | Genentech, Inc. | Oxadiazole transient receptor potential channel inhibitors |
| GB201901757D0 (en) | 2019-02-08 | 2019-03-27 | Syngenta Crop Protection Ag | Herbicidal compounds |
| US11884652B2 (en) * | 2020-06-29 | 2024-01-30 | Boehringer Ingelheim International Gmbh | Tetrazole derivatives as TRPA1 inhibitors |
| US11891403B2 (en) * | 2020-06-29 | 2024-02-06 | Boehringer Ingelheim International Gmbh | Tetrazole derivatives as TRPA1 inhibitors |
| FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
| CN112794860B (zh) * | 2021-03-24 | 2021-06-29 | 上海肇钰医药科技有限公司 | 噁唑嘧啶酮酰胺类化合物或其可药用盐，制备方法及用途 |
| JP7602061B2 (ja) * | 2021-04-14 | 2024-12-17 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ＴＲＰＡ１阻害剤としてのイミダゾ［４，５－ｄ］ピリダジノニル誘導体 |
| IL306065A (en) * | 2021-04-14 | 2023-11-01 | Boehringer Ingelheim Int | Uracil history as TRPA1 inhibitors |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| CN118206482B (zh) * | 2024-03-05 | 2025-04-25 | 山东京博生物科技有限公司 | 一种4-三氟甲基烟酰胺的合成方法 |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| CH583213A5 (enExample) * | 1973-05-21 | 1976-12-31 | Ciba Geigy Ag | |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| EP0102324A3 (de) | 1982-07-29 | 1984-11-07 | Ciba-Geigy Ag | Lipide und Tenside in wässriger Phase |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4500653A (en) * | 1983-09-14 | 1985-02-19 | Mobay Chemical Corporation | Blowing agents for thermoplastic compositions |
| US5004697A (en) | 1987-08-17 | 1991-04-02 | Univ. Of Ca | Cationized antibodies for delivery through the blood-brain barrier |
| US5268164A (en) | 1990-04-23 | 1993-12-07 | Alkermes, Inc. | Increasing blood-brain barrier permeability with permeabilizer peptides |
| US5112596A (en) | 1990-04-23 | 1992-05-12 | Alkermes, Inc. | Method for increasing blood-brain barrier permeability by administering a bradykinin agonist of blood-brain barrier permeability |
| AU677216B2 (en) | 1992-07-27 | 1997-04-17 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | Targeting of liposomes to the blood-brain barrier |
| US6514221B2 (en) | 2000-07-27 | 2003-02-04 | Brigham And Women's Hospital, Inc. | Blood-brain barrier opening |
| AU2001286930A1 (en) | 2000-08-30 | 2002-03-13 | The Board Of Trustees Of The Leland Stanford Junior University | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7034036B2 (en) | 2000-10-30 | 2006-04-25 | Pain Therapeutics, Inc. | Inhibitors of ABC drug transporters at the blood-brain barrier |
| DE10121982B4 (de) | 2001-05-05 | 2008-01-24 | Lts Lohmann Therapie-Systeme Ag | Nanopartikel aus Protein mit gekoppeltem Apolipoprotein E zur Überwindung der Blut-Hirn-Schranke und Verfahren zu ihrer Herstellung |
| EP2147679B1 (en) | 2001-07-25 | 2014-06-25 | Raptor Pharmaceutical, Inc. | Compositions for blood-brain barrier transport |
| US20030162695A1 (en) | 2002-02-27 | 2003-08-28 | Schatzberg Alan F. | Glucocorticoid blocking agents for increasing blood-brain barrier permeability |
| US7220833B2 (en) | 2002-12-03 | 2007-05-22 | Thomas Nelson | Artificial low-density lipoprotein carriers for transport of substances across the blood-brain barrier |
| JP2007505142A (ja) | 2003-09-10 | 2007-03-08 | セダーズ−シナイ メディカル センター | 血液脳関門を通過する薬剤のカリウムチャネル媒介性送達 |
| AR065860A1 (es) * | 2007-03-29 | 2009-07-08 | Novartis Ag | 3-imidazolil-indoles para el tratamiento de enfermedades proliferativas |
| WO2011114184A1 (en) * | 2010-03-15 | 2011-09-22 | Glenmark Pharmaceuticals S.A. | Amides of heterocyclic compounds as trpa1 inhibitors |
| WO2017060488A1 (en) * | 2015-10-09 | 2017-04-13 | Almirall, S.A. | New trpa1 antagonists |
| WO2017064068A1 (en) | 2015-10-14 | 2017-04-20 | Almirall, S.A. | New trpa1 antagonists |
-
2017
- 2017-11-27 TW TW106141249A patent/TW201831477A/zh unknown
- 2017-11-27 JP JP2019527497A patent/JP7171567B2/ja active Active
- 2017-11-27 EP EP17804551.4A patent/EP3544979B1/en active Active
- 2017-11-27 CN CN201780083499.9A patent/CN110225911B/zh active Active
- 2017-11-27 WO PCT/EP2017/080571 patent/WO2018096159A1/en not_active Ceased
-
2019
- 2019-05-23 US US16/421,114 patent/US10913742B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535761A5 (enExample) | ||
| JP2021105002A5 (enExample) | ||
| RU2016115868A (ru) | Замещенные гетероциклические сульфонамидные соединения, полезные в качестве модуляторов trpa 1 | |
| DE69533408T2 (de) | Chinolinderivate als Tachykinin NK3 Rezeptor Antagonisten | |
| JP2018513107A5 (enExample) | ||
| JP5531370B2 (ja) | プロスタグランジンｄ２受容体のアンタゴニスト | |
| US8034826B2 (en) | Cycloalkane[B]azaindole antagonists of prostaglandin D2 receptors | |
| JP2021046404A5 (enExample) | ||
| JP2021508686A5 (enExample) | ||
| JP2017503813A5 (enExample) | ||
| JP2005509024A5 (enExample) | ||
| RU2010126063A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола как агонисты в2 адренергического рецептора | |
| JP2009503107A (ja) | スフィンゴシンキナーゼ阻害剤およびそれらの使用方法 | |
| JP2016500111A5 (enExample) | ||
| JPH057386B2 (enExample) | ||
| RU2005135016A (ru) | Производные хинолина в качестве ингибиторов фосфодиэстеразы | |
| JP2015503505A5 (enExample) | ||
| JP2016532673A5 (enExample) | ||
| JP2004516278A (ja) | 一酸化窒素合成酵素阻害物質であるリン酸塩 | |
| RU2014150338A (ru) | Соединение как ингибитор передачи сигналов wnt, его композиции и применение | |
| JP2005525323A5 (enExample) | ||
| JP7143295B2 (ja) | ピペリジン－２，６－ジオン誘導体及びクローン病の治療 | |
| JP2018529737A5 (enExample) | ||
| JP2017526724A5 (enExample) | ||
| RU2010139571A (ru) | Производные 4-(2-амино-1-гидроксиэтил)фенола в качестве агонистов b2-адренергического рецептора |